Barclays PLC Increases Stock Position in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT)

Barclays PLC lifted its holdings in Phathom Pharmaceuticals, Inc. (NASDAQ:PHATFree Report) by 366.0% during the third quarter, Holdings Channel reports. The institutional investor owned 57,807 shares of the company’s stock after acquiring an additional 45,402 shares during the quarter. Barclays PLC’s holdings in Phathom Pharmaceuticals were worth $1,044,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Geode Capital Management LLC boosted its stake in Phathom Pharmaceuticals by 7.1% during the third quarter. Geode Capital Management LLC now owns 862,918 shares of the company’s stock worth $15,605,000 after acquiring an additional 56,871 shares in the last quarter. MML Investors Services LLC increased its stake in shares of Phathom Pharmaceuticals by 72.8% during the third quarter. MML Investors Services LLC now owns 33,860 shares of the company’s stock valued at $612,000 after purchasing an additional 14,260 shares in the last quarter. State Street Corp lifted its holdings in shares of Phathom Pharmaceuticals by 17.5% during the third quarter. State Street Corp now owns 922,788 shares of the company’s stock valued at $16,684,000 after purchasing an additional 137,539 shares during the last quarter. Point72 Asset Management L.P. bought a new stake in shares of Phathom Pharmaceuticals in the 3rd quarter worth approximately $7,952,000. Finally, Portolan Capital Management LLC grew its stake in shares of Phathom Pharmaceuticals by 50.4% in the 3rd quarter. Portolan Capital Management LLC now owns 1,699,918 shares of the company’s stock worth $30,735,000 after buying an additional 569,829 shares during the last quarter. 99.01% of the stock is owned by hedge funds and other institutional investors.

Phathom Pharmaceuticals Stock Up 2.6 %

Shares of PHAT opened at $6.79 on Wednesday. Phathom Pharmaceuticals, Inc. has a twelve month low of $6.07 and a twelve month high of $19.71. The company has a market capitalization of $464.28 million, a P/E ratio of -1.19 and a beta of 0.56. The firm has a 50 day moving average of $8.96 and a 200 day moving average of $12.69.

Analyst Upgrades and Downgrades

PHAT has been the subject of a number of recent research reports. Needham & Company LLC reiterated a “buy” rating and set a $28.00 price objective on shares of Phathom Pharmaceuticals in a research note on Friday, January 10th. HC Wainwright restated a “buy” rating and set a $28.00 price target on shares of Phathom Pharmaceuticals in a report on Thursday, December 12th.

View Our Latest Stock Report on PHAT

Insider Buying and Selling at Phathom Pharmaceuticals

In other Phathom Pharmaceuticals news, Director Frank Karbe acquired 12,500 shares of the company’s stock in a transaction that occurred on Friday, December 13th. The shares were bought at an average cost of $7.93 per share, with a total value of $99,125.00. Following the completion of the transaction, the director now directly owns 57,000 shares of the company’s stock, valued at approximately $452,010. This represents a 28.09 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 24.10% of the company’s stock.

Phathom Pharmaceuticals Company Profile

(Free Report)

Phathom Pharmaceuticals, Inc, biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach.

Featured Articles

Want to see what other hedge funds are holding PHAT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Phathom Pharmaceuticals, Inc. (NASDAQ:PHATFree Report).

Institutional Ownership by Quarter for Phathom Pharmaceuticals (NASDAQ:PHAT)

Receive News & Ratings for Phathom Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phathom Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.